Company News for Sep 9, 2026

Qualcomm gained 3.2% on optimism around a new Amazon Web Services data-center partnership and AI growth prospects, while Roivant surged 18.8% after positive Phase 2 mosliciguat data in pulmonary hypertension. Bloom Energy rose 9.6% following its addition to the S&P 500. Offsetting these gains, Novartis fell 13.9% after its Phase 3 del-desiran study failed to significantly improve outcomes in myotonic dystrophy type 1.

Analysis

QCOM’s upside depends less on an initial cloud-revenue contribution than on whether the AWS relationship validates Qualcomm as a second-source inference silicon supplier. The strategic read-through is strongest for Arm-based server CPUs and edge-to-cloud AI deployments, where QCOM can monetize connectivity, compute and licensing; it is not yet a credible challenge to NVDA’s accelerator economics. Over the next 1-3 months, watch for disclosed AWS instance availability, customer benchmarks and incremental data-center revenue guidance—without these, the valuation impact should remain narrative-driven.

ROIV’s move is a classic biotech de-risking event, but the next leg requires durability, safety, dose-response and a credible registrational design rather than a headline efficacy signal. Pulmonary-hypertension assets can command substantial strategic value if differentiated on tolerability or combination use, yet the addressable market and probability-adjusted value are highly sensitive to trial details absent here. NVS’s selloff may be mechanically excessive given diversification, but it also raises the probability that investors begin applying a larger pipeline-risk discount ahead of subsequent late-stage readouts.

BE’s index inclusion creates a near-term technical bid from passive and benchmark-aware managers, followed by a greater risk of reversal once forced buying ends. The more important 6-18 month issue is whether data-center power scarcity converts customer interest into bankable, high-margin deployments; BE remains exposed to financing costs, natural-gas input economics and execution on service margins. NNOX is promotional noise in this dataset rather than an independently actionable catalyst.

Key Decisions for Investors

• Maintain a tactical long QCOM position for 1-3 months only if management provides quantifiable AWS deployment or data-center revenue commentary; use a 7-8% stop from entry. Upside is multiple expansion on credible AI infrastructure validation, while lack of disclosed economics should cap the move.
• Do not chase ROIV after the gap. Place an alert for full Phase 2 data, especially adverse events, functional endpoints and durability; initiate only if the market’s implied probability remains below a defensible Phase 3 success estimate after reviewing those details. Size as a binary-event position, not a core healthcare holding.
• Trade BE’s inclusion flow opportunistically: take profits or consider a small short 3-10 trading days after the effective rebalance if the stock materially outperforms the S&P 500 without new bookings or margin guidance. Cover on evidence of signed data-center contracts or upward revision to EBITDA/FCF expectations.
• Monitor NVS for a staged long entry over 1-3 months rather than treating the pipeline setback as a broad thesis break. Add only if management reaffirms medium-term growth guidance and the drawdown is not accompanied by negative read-throughs across other late-stage programs.